Skip to main content

Table 5 Univariate and multivariate analyses of characteristics for successful trial completion (having results on ClinicalTrials.gov)

From: Characteristics of clinical trials related to hip fractures and factors associated with completion

Characteristics

Rates

Simple logistic regression

Multiple logistic regression

OR (95% CI)

P

OR (95% CI)

P

Outcome measures including mortality

 Yes

6.25% (5/80)

0.64 (0.24–1.67)

0.36

1.25 (0.35–4.49)

0.73

 No

9.49% (37/390)

Gender

 Male

25.00% (1/4)

2.08 (0.35–12.28)

0.42

3.07 (0.42–22.46)

0.27

 Female

6.67% (1/15)

 Both

8.87% (40/451)

Age including children

 Yes

5.00% (2/40)

0.51 (0.12–2.21)

0.37

1.30 (0.22–7.63)

0.77

 No

9.30% (40/430)

Age including older adults

 Yes

8.89% (41/461)

0.78 (0.10–6.40)

0.82

0.96 (0.08–11.59)

0.97

 No

11.11% (1/9)

Phases

 Not applicable

5.71% (18/315)

1.30 (1.08–1.55)

 < 0.01

1.05 (0.77–1.44)

0.74

 Phase 1

0.00% (0/4)

 Phase 2

25.93% (7/27)

 Phase 3

16.33% (8/49)

 Phase 4

12.00% (9/75)

Enrollment

  ≤ 50

12.90% (16/124)

0.89 (0.69–1.15)

0.39

0.71 (0.51–0.99)

0.04

  > 50 and ≤ 100

7.14% (9/126)

  > 100 and ≤ 200

6.60% (7/106)

  > 200 and ≤ 400

7.35% (5/68)

  > 400

10.87% (5/46)

Funded by the NIH

 Yes

33.33% (6/18)

5.78 (2.05–16.31)

 < 0.01

7.55 (1.48–38.56)

0.02

 No

7.96% (36/452)

Funded by industry

 Yes

23.61% (17/72)

4.61 (2.34–9.09)

 < 0.01

6.32 (2.43–16.44)

 < 0.01

 No

6.28% (25/398)

Allocation

 Not applicable

1.92% (1/52)

1.53 (0.82–2.85

0.18

1.28 (0.42–3.92)

0.66

 Non-randomized

13.89% (5/36)

 Randomized

9.42% (36/382)

Intervention model

 Single

3.85% (3/78)

1.30 (0.89–1.91)

0.18

1.54 (0.76–3.10)

0.23

 Sequential

0.00% (0/3)

 Parallel

10.19% (37/363)

 Factorial

11.11% (1/9)

 Crossover

5.88% (1/17)

Masking

 None

9.68% (18/186)

1.24 (0.99–1.56)

0.06

0.83 (0.59–1.17)

0.28

 Single

4.80% (6/125)

 Double

3.61% (3/83)

 Triple

21.43% (6/28)

 Quadruple

18.75% (9/48)

Primary purpose

  Diagnostic

  Yes

6.25% (1/16)

0.67 (0.09–5.21)

0.70

0.41 (0.01–24.96)

0.67

  No

9.03% (41/454)

 Health service research

  Yes

0.00% (0/13)

0.01 (0.00–99.99)

0.98

0.01 (0.00–99.99)

0.98

  No

9.19% (42/457)

 Prevention

  Yes

13.51% (10/74)

1.78 (0.83–3.79)

0.14

1.20 (0.10–14.56)

0.89

  No

8.08% (32/396)

 Supportive care

  Yes

0.00% (0/27)

0.01 (0.00–99.99)

0.98

0.01 (0.00–99.99)

0.98

  No

9.48% (42/443)

 Treatment

  Yes

9.38% (30/320)

1.19 (0.59–2.39)

0.63

0.70 (0.07–7.40)

0.77

  No

8.00% (12/150)

Interventions

 Behavioral

  Yes

2.94% (1/34)

0.29 (0.04–2.19)

0.23

0.18 (0.01–2.52)

0.20

  No

9.40% (41/436)

 Drug/biological

  Yes

17.61% (25/142)

3.91 (2.04–7.50)

 < 0.01

4.47 (1.19–16.83)

0.03

  No

5.18% (17/328)

 Device

  Yes

12.17% (14/115)

1.62 (0.82–3.19)

0.16

2.53 (0.77–8.29)

0.12

  No

7.89% (28/355)

 Procedure

  Yes

4.55% (6/132)

0.40 (0.16–0.97)

0.04

0.99 (0.34–2.90)

0.99

  No

10.65% (36/338)

 Location in China

  Yes

4.55% (2/44)

0.46 (0.11–1.97)

0.30

1.91 (0.26–13.86)

0.52

  No

9.39% (40/426)

 Location in the United States

  Yes

29.00% (29/100)

11.22 (5.56–22.63)

 < 0.01

9.43 (2.41–36.95)

 < 0.01

  No

3.51% (13/370)

 Location in Europe

  Yes

3.06% (6/196)

0.21 (0.09–0.51)

 < 0.01

0.89 (0.20–4.00)

0.88

  No

13.14% (36/274)

 Location in Canada

  Yes

6.45% (2/31)

0.69 (0.16–2.99)

0.62

1.96 (0.25–15.67)

0.53

  No

9.11% (40/439)

  1. OR Odds rates, NIH National Institutes of Health, CI Confidence intervals